URC 2022 Early Bird (ends 3 July 2022)
SG$250.00
URC 2022 Early Bird (ends 3 July 2022)
Choose Your Platform to share!
About the Author: ruey
Dr Rajeev TP
Laboris veniam culpa et nisi sunt non. Elit ut consequat aliquip duis. Occaecat ullamco in Lorem consequat quis. Incididunt officia eu ex est.
Irure incididunt anim pariatur exercitation. Irure incididunt proident pariatur est officia proident ex occaecat incididunt. Non minim amet proident mollit nulla ullamco sunt labore.
Consequat eiusmod ipsum nulla laborum id proident fugiat est. Consectetur exercitation anim in esse reprehenderit. Duis ex eiusmod quis officia dolore cupidatat.
Dr Ranjith Ramasamy
Laboris veniam culpa et nisi sunt non. Elit ut consequat aliquip duis. Occaecat ullamco in Lorem consequat quis. Incididunt officia eu ex est.
Irure incididunt anim pariatur exercitation. Irure incididunt proident pariatur est officia proident ex occaecat incididunt. Non minim amet proident mollit nulla ullamco sunt labore.
Consequat eiusmod ipsum nulla laborum id proident fugiat est. Consectetur exercitation anim in esse reprehenderit. Duis ex eiusmod quis officia dolore cupidatat.
Dr Uttam Kumar Mete
Laboris veniam culpa et nisi sunt non. Elit ut consequat aliquip duis. Occaecat ullamco in Lorem consequat quis. Incididunt officia eu ex est.
Irure incididunt anim pariatur exercitation. Irure incididunt proident pariatur est officia proident ex occaecat incididunt. Non minim amet proident mollit nulla ullamco sunt labore.
Consequat eiusmod ipsum nulla laborum id proident fugiat est. Consectetur exercitation anim in esse reprehenderit. Duis ex eiusmod quis officia dolore cupidatat.
A/Prof Suman Chapagain
Laboris veniam culpa et nisi sunt non. Elit ut consequat aliquip duis. Occaecat ullamco in Lorem consequat quis. Incididunt officia eu ex est.
Irure incididunt anim pariatur exercitation. Irure incididunt proident pariatur est officia proident ex occaecat incididunt. Non minim amet proident mollit nulla ullamco sunt labore.
Consequat eiusmod ipsum nulla laborum id proident fugiat est. Consectetur exercitation anim in esse reprehenderit. Duis ex eiusmod quis officia dolore cupidatat.
Prof Tai-Lung Cha
Dr. Cha is the Distinguished Investigator and Director of the National Institute of Cancer Research, National Health Research Institute, Professor of the Division of Urology, Department of Surgery, TSGH, NDMC, as well as Jointly Appointed Professor of Genomics Research Center, Academia Sinica. Dr. Cha received his MD degree from the School of Medicine, National Defense Medical Center in 1990. He got his PhD degree from GSBS, The University of Texas, MD Anderson Cancer Center in 2005.
Upon his return to Taiwan, he served as a surgeon-scientist dedicated to cancer diagnosis and treatment, along with his active participation in international anti-cancer drug development clinical trials worldwide, which has afforded him a profound understanding of the entire spectrum of cancer research. During his tenure as the full professor of the National Defense Medical Center, he was invited to be the convener of the Department of Nephrology, Urology, and Metabolism at the National Science Council, he possesses a comprehensive understanding of the nation’s scientific research direction and key points that would contribute to the advancement and connection of the basic and clinical research.
Dr. Cha has played numerous leadership roles in medicine and research. He served the Presidentship in NDMC and is a member of the Taiwan Medical Education Evaluation Committee, he strives to align Taiwan’s medical education with international standards collaboratively. Additionally, his involvement in the Medical Policy Council, directorship and supervision of the Health Policy Council, and roles in the National Innovation Award’s academic research and corporate innovation committees. He hasserved as the director of the Acer Foundation and the Revitalization Hospitals. He received the 2021 National Excellent Teacher Award from the Ministry of Education and was listed in the World’s Top 2% Scientists 2021. Dr. Cha’s research interests concentrated on unraveling the mechanisms of cancer metastasis and progression and discovering innovative cancer treatments. His lab uncovered a novel cancer mitochondrial regulatory mechanism and identified a drug combination targeting this mechanism. This study was transferred to a biotechnology company.
After completing pre-clinical animal toxicity testing, this new drug combination obtained IND approval in Taiwan and the United States. Dr. Cha initiated and completed a Phase I clinical trial to assess the drug’s safety and preliminary efficacy for patients with advanced kidney cancer and other cancers resistant to multiple drug treatments. The biotechnology company collaborated with six medical centers in Australia for Phase I and Phase IIa clinical trials, leading to the prestigious 13th National Innovation Award. Over the past decade, Dr. Cha’s Lab identified a novel G protein-coupled receptor, mediating the evolution of cancer metastasis in various cancer types. Dr. Cha elucidated the fundamental molecular mechanisms governing the transition of cancer cells from paracrine to autocrine signaling regulation through the novel GPCR pathway.
Prof Alexander Haese
Dr. Alexander Haese is a distinguished Professor of Urology and the Director of the Robot-assisted Urologic Surgery Program at the Martini-Clinic Prostate Cancer Center, University Clinic Hamburg-Eppendorf, Germany. With over 25 years of experience in urology and specialized expertise in robotic-assisted surgery, Dr. Haese is recognized as a leading figure in the field.
Dr. Haese has been an integral part of Martini-Clinic since 2008, having completed close to 5000 robot prostatectomies and has trained over 150 surgeons across 11 countries as a proctor for Intuitive Surgical.
His pioneering work in the early detection and management of prostate cancer has earned him numerous accolades, including the G.E. Konjetzny Prize of the Hamburg Cancer Society. Dr. Haese has also contributed to advancing scientific understanding through his research and has been awarded fellowship grants to work at Johns Hopkins University, focusing on the role of human glandular kallikrein 2 in prostate cancer.
An accomplished researcher, he has published extensively and serves as a reviewer for leading urology journals. Dr. Haese is a member of several professional organizations, including the German, European, and American Associations of Urology, underscoring his commitment to advancing the field both nationally and internationally.